Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 7,034 | -99,560 | 41,955 | 15,909 | 41,980 |
| Depreciation Amortization | 89,093 | 74,586 | 74,746 | 98,708 | 54,454 |
| Income taxes - deferred | 6,477 | 20,621 | 15,615 | -7,945 | 10,872 |
| Accounts receivable | -10,742 | -7,748 | -7,159 | -2,079 | -10,434 |
| Accounts payable and accrued liabilities | -5,598 | 3,084 | 916 | 6,272 | -10,262 |
| Other Working Capital | -40,441 | -15,555 | -44,625 | -16,433 | -25,509 |
| Other Operating Activity | 106,171 | 213,961 | 73,201 | 50,842 | 64,616 |
| Operating Cash Flow | $151,994 | $189,389 | $154,649 | $145,274 | $125,717 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -1,250 | N/A | -6,758 | -13,000 | -17,187 |
| PPE Investments | -15,333 | -10,636 | -15,161 | -30,076 | -45,866 |
| Net Acquisitions | -16,702 | N/A | N/A | -32,000 | -424,042 |
| Purchase Of Investment | -141,041 | -252,212 | -137,608 | -387,685 | -602,431 |
| Sale Of Investment | 273,807 | 179,572 | 237,068 | 237,576 | 1,068,736 |
| Investing Cash Flow | $99,481 | $-83,276 | $77,541 | $-225,185 | $-20,790 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 101,000 | 287,500 | 149,550 | N/A | 363,750 |
| Debt Repayment | -317,799 | -210,885 | -330,312 | -427,694 | N/A |
| Common Stock Issued | 3,303 | 2,298 | 4,750 | 27,341 | 26,655 |
| Common Stock Repurchased | -148,328 | -25,000 | N/A | N/A | N/A |
| Other Financing Activity | -7,803 | -36,550 | -7,019 | -1,175 | -9,711 |
| Financing Cash Flow | $-369,627 | $17,363 | $-183,031 | $-401,528 | $380,694 |
| Exchange Rate Effect | -77 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 276,774 | 153,298 | 104,139 | 585,578 | 99,957 |
| End Cash Position | 158,545 | 276,774 | 153,298 | 104,139 | 585,578 |
| Net Cash Flow | $-118,229 | $123,476 | $49,159 | $-481,439 | $485,621 |
| Free Cash Flow | |||||
| Operating Cash Flow | 151,994 | 189,389 | 154,649 | 145,274 | 125,717 |
| Capital Expenditure | -15,333 | -10,636 | -15,161 | -30,076 | -45,866 |
| Free Cash Flow | 136,661 | 178,753 | 139,488 | 115,198 | 79,851 |